Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVE™, to develop differentiated small molecule therapeutics, today announced that its partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01) – an oral NLRP3 inhibitor licensed by Novo Nordisk in September 2022. “.

Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk

An EU study confirms there's no evidence linking Ozempic and Wegovy to an increase in suicidal thoughts. Side effects could be a key differentiator when it comes to which weight-loss and diabetes drugs succeed.

This Is a Huge Sigh of Relief for Novo Nordisk Investors

Amgen

Shares in Danish drugmaker Novo Nordisk dropped as much as 5.3% on Friday, set for their biggest one-day fall since August 2022, after rival Amgen said it was encouraged by interim trial data on its experimental obesity drug.

Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data

Novo Nordisk said it will cut prices of Wegovy amid rising sales and competition. Sales of the blockbuster drug more than doubled in the first quarter year-on-year.

Blockbuster weight loss drug Wegovy's sales just doubled — and could heat up even more with a price cut

Danish drugmaker Novo Nordisk, the creator of Ozempic and Wegovy, announced a shocking statistic Thursday: Over 25,000 people begin Wegovy each week. The number is five times larger than the numbers from December—about 5,000 new users a week.

25,000 people begin taking Wegovy each week, but Novo Nordisk stock is sinking anyway

Novo Nordisk A/S (NVO) Q1 2024 Earnings Conference Call May 2, 2024 7:00 AM ET Company Participants Lars Fruergaard Jørgensen - Chief Executive Officer Camilla Sylvest - Executive Vice President, Head of Commercial Strategy & Corporate Affairs Doug Langa - Executive Vice President, Head of North America Operations Martin Holst Lange - Executive Vice President, Head of Development Karsten Munk Knudsen - Chief Financial Officer Daniel Bohsen - Head of Investor Relations Conference Call Participants Michael Nedelcovych - TD Cowen Richard Vosser - JPMorgan Louise Chen - Cantor Fitzgerald Evan Seigerman - BMO Capital Markets Sachin Jain - Bank of America Peter Verdult - Citi Simon Baker - Redburn Atlantic Florent Cespedes - Bernstein Mark Purcell - Morgan Stanley Harry Sephton - UBS Richard Parkes - BNP Paribas Exxon Michael Novod - Nordea Operator Good day! And thank you for standing by.

Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript

Novo Nordisk (NYSE:NVO), Europe's biggest company, said it is ramping up production of its diabtes/weightloss drugs Wegovy and Ozempic, after patient numbers quadrupled in the US. But the Danish colossus said it has cut the price of its blockbuster injected treatment due to competition from rivals like Eli Lilly.

Novo Nordisk ups guidance buts cuts Wegovy price

Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.

Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales

Moderna

Here are two biotech stocks to watch after their recent earnings report.

2 Biotech Stocks To Watch Today Amid Earnings

Novo Nordisk (NVO) reported first-quarter earnings Thursday that beat analysts' estimates as demand surged for its weight loss drugs, Ozempic and Wegovy.

Novo Nordisk's Earnings Beat Estimates on Surging Demand for Its Weight-Loss Drugs

Novo Nordisk has seen the price of its hugely popular weight-loss drug Wegovy and diabetes drug Ozempic fall in the United States as volumes and competition have increased, a senior executive said on Thursday.

Novo Nordisk: Wegovy, Ozempic prices in US fell in Q1

Novo Nordisk stock came under mild selling pressure early Thursday, after the company reported Q1 results and lifted guidance.

Novo Nordisk Dips As Q1 Wegovy Sales Double, But Miss Target

Novo Nordisk raised its full-year guidance to reflect better pricing in the U.S. and as global demand for its hit weight-loss and diabetes drugs continues to outstrip supply.

WegovySales More Than Double as Demand Soars

Novo Nordisk (NYSE:NVO), Europe's biggest company, said it is ramping up production of its diabtes/weightloss drugs Wegovy and Ozempic, after patient numbers quadrupled in the US. First-quarter sales came in at 65.35 billion Danish krone, beating forecasts of DKK 63.75 billion, including almost DKK 35 billion from the drug.

Novo Nordisk ups guidance after earnings beat expectations

The Danish pharmaceutical giant, which became Europe's most valuable company last year, said Wegovy sales jumped 106% in the first quarter.

Novo Nordisk Hikes Guidance as Weight-Loss Drug Sales Surge. Why the Stock's Falling.

Danish pharma giant Novo Nordisk raised its 2024 outlook and beat first-quarter profit expectations in its first-quarter earnings report Thursday morning, amid a frenzied rush to match booming consumer demand for its popular weight loss and diabetes drugs Ozempic and Wegovy.

Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug Frenzy

Novo Nordisk said its Wegovy injectable drug for weight loss now has more than 130,000 weekly prescriptions in North America alone after boosting supplies to meet insatiable demand.

Novo Nordisk now has more than 130,000 weight-loss prescriptions as it hikes financial outlook

This morning, pharmaceuticals reported triumphant Q1 2024 financial results before markets opened. One of the more memorable highlights was certainly the fact that Novo Nordisk's sales increased by 22% in Danish kroner (by 24% at constant exchange rates) to DKK 65.3 billion for the period.

Earnings report: Novo Nordisk cashes in on weight loss drug fever with better-than-expected results

Sales of popular weight loss drug Wegovy more than doubled to 9.38 billion kroner.

Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than double

Novo Nordisk posted on Thursday first-quarter operating profit above analyst forecasts, as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from Eli Lilly.

Obesity drugmaker Novo Nordisk's Q1 profit beats forecast

Bagsværd, Denmark, 2 May 2024 - financial report for the period 1 January 2024 to 31 March 2024 Operating profit increased by 27% in Danish kroner and by 30% at constant exchange rates (CER) to DKK 31.8 billion. Sales in North America Operations increased by 34% in Danish kroner (35% at CER).

Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024

Eli Lilly

Online pharmacies and slimming clinics are cutting prices for Wegovy and Mounjaro in Britain just months after the weight-loss drugs were launched there, as initial supply shortages ease.

Wegovy, Mounjaro prices cut as British pharmacies compete for weight-loss patients

Bank of America

Mastercard

To paraphrase Rudyard Kipling, the secret to success in the stock market is to “keep your head when all about you are losing theirs.” When everyone is panicking and sending the market lower, that's the time for you to be cool as a cucumber and look for stocks to buy on dips.

Profit from the Panic: 3 Stocks to Pounce on When They Become Steals

Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , said on Wednesday it plans to invest around $200 million in quantum computing startups.

Novo Nordisk owner to invest $200 million in quantum computing startups

Hermes International

TotalEnergies SE

UBS says investors should forget about the Magnificent Seven and look across the Atlantic to 18 European stocks they've highlighted that account for approximately 25% of the Stoxx Europe 600 Index, the exact weighting as the Mag 7 when initially conceived in 2023.  At least with the Mag 18, you have 18 choices rather than just seven.

News for Novo Nordisk Stock (NVO)